Grifols (GRFS) Projected to Release Earnings on Monday

Grifols (NASDAQ:GRFS) is projected to issue its Q3 2026 resultson Monday, November 2nd. Analysts expect the company to announce earnings of $0.3202 per share and revenue of $2.21 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 12:30 PM ET.

Grifols Trading Down 0.5%

NASDAQ GRFS traded down $0.04 on Wednesday, hitting $8.06. The company’s stock had a trading volume of 80,521 shares, compared to its average volume of 637,970. Grifols has a 52-week low of $6.96 and a 52-week high of $9.90. The company’s 50-day simple moving average is $7.59 and its 200 day simple moving average is $8.03.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on GRFS. Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, August 17th. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. cut their price target on shares of Grifols from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Monday. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Grifols presently has an average rating of “Reduce” and an average price target of $9.00.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.